Physician Confronts Reviewer Who Stole Study

  • Home Blog Physician confronts reviewer who stole study

Physician Confronts Reviewer Who Stole Study

Dec 14, 2016

A former peer reviewer for the Annals of Internal Medicine has admitted to taking a paper rejected from that journal, changing the author names and title, and publishing it as his own in another journal.  The true author of the study, Michael Dansinger, MD, from Tufts Medical Center in Boston, Massachusetts, published an open letter to the plagiarist in the Annals of Internal Medicine. The reviewer, Carmine Finelli, MD, PhD, from the Stella Maris Mediterraneum Foundation, Chiaromonte, Potenza, Italy, does not dispute the facts, according to both Dr. Dansinger, and Christine Laine, MD, MPH, Annals editor-in-chief, who wrote an editorial published online alongside Dr Dansinger’s letter.

To know more, click Physician Confronts Reviewer.

Downloads

Article in PDF

Recent Articles
medtech-news-for-endospan-boston-scientific-ge-healthcare
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Oct 24, 2024

iRhythm’s Zio® AT Device Improvements Receive FDA Clearance; Epitel Adds REMI AI Device to Portfolio with Fourth FDA 510(k); SeaStar Medical Advances Acute Kidney Injury Trial, Approaches Interim Analysis; Endospan Completes Primary Enrollment for TRIOMPHE Study of NEXUS® Stent Graft; Boston Scientific Enhances FARAPULSE™ PFA with New Cardiac Mapping Technology; GE HealthCare Debuts CareIntellect to Support Oncologists with AI-Enhanced Patient Insights

role-of-plasma-protein-therapeutics
Articles

Oct 23, 2024

Plasma Proteins Therapeutics: Transforming Treatment in Hematology and Beyond

pharma-news-for-gilead-merck-astellas
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Oct 22, 2024

Gilead and Merck Announce Encouraging Phase II Results of Islatravir and Lenacapavir Combo; REGENXBIO Highlights Positive Data from Phase II ABBV-RGX-314 Wet AMD Study at AAO 2024; FDA Greenlights Astellas’ VYLOY for Advanced Gastric and GEJ Cancer Therapy; Merck’s CAPVAXIVE Vaccine Yields Strong Immune Response in Adults Vulnerable to Pneumococcal Disease; FDA Postpones LUMAKRAS Colorectal Cancer Verdict to Early 2025

Colorectal Cancer
FDA
gastroesophageal junction adenocarcinoma
HIV
KRAZATI
Latest pharma news
Lumakras
Non-small cell lung cancer
NSCLC
pharma news
pneumococcal disease
recent pharma news
WET AMD
loader